<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sublingual immunotherapy for allergic rhinitis and conjunctivitis: SLIT-tablets</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sublingual immunotherapy for allergic rhinitis and conjunctivitis: SLIT-tablets</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sublingual immunotherapy for allergic rhinitis and conjunctivitis: SLIT-tablets</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter S Creticos, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allergen immunotherapy for the treatment of allergic respiratory diseases has traditionally been administered by subcutaneous injections. Subcutaneous immunotherapy (SCIT) has proven efficacy in allergic rhinoconjunctivitis and asthma, but it requires regular injections at a clinician's office (typically over a period of three to five years) and carries the risk of potentially serious systemic allergic reactions, including anaphylaxis, in response to the treatment itself.</p><p>Sublingual immunotherapy (SLIT) is an alternate approach of administering allergens orally, and more specifically with a sublingual methodology in which the allergen is given as either a dissolvable tablet (under the tongue) or as an aqueous or liquid extract. SLIT-tablets offer several specific advantages over injection immunotherapy. The tablet can be self-administered by patients or caregivers, does not require injections, and carries a much lower risk of serious systemic allergic reactions compared with SCIT. SLIT-drops (liquid extract) are used in other parts of the world but are not approved by the US Food and Drug Administration (FDA).</p><p>This topic will discuss the SLIT-tablet forms of treatment that have been approved by either the US FDA and/or Canadian, European, and Asian regulatory authorities. The article will focus on appropriate patient selection, dose regimens and method of administration, the evidence-based clinical data to support its safety and efficacy, its use in patients with asthma, and its advantages and limitations.</p><p>The use of SCIT for the treatment of allergic respiratory diseases is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15757.html" rel="external">"SCIT: Standard schedules, administration techniques, adverse reactions, and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13526.html" rel="external">"Subcutaneous aeroallergen immunotherapy: Accelerated schedules (cluster and rush)"</a>.)</p><p></p><p>Oral immunotherapy for the treatment of other allergic diseases is also reviewed separately. (See  <a class="medical medical_review" href="/d/html/2410.html" rel="external">"Experimental therapies for food allergy: Immunotherapy and nonspecific therapies"</a>.)</p><p class="headingAnchor" id="H2"><span class="h2">Background</span><span class="headingEndMark"> — </span>Oral approaches to immunotherapy were first tried in the early 1900s. Through the years, allergen materials became better characterized and various delivery systems were developed, including oral solutions that were either swallowed or swished in the mouth but then expectorated, administered as enteric-coated tablets, liposomal constructs, or microencapsulated polymers [<a href="#rid1">1,2</a>].</p><p>In 1998, the World Health Organization (WHO) recognized that SLIT was a promising alternate mode of immunotherapy and encouraged continued clinical investigation into this form of treatment [<a href="#rid3">3</a>].<strong> </strong>In 2009, the World Allergy Organization (WAO) published their opinion that the cumulative evidence showed SLIT represented a viable alternative to SCIT and encouraged continued clinical investigation to characterize optimal techniques [<a href="#rid4">4,5</a>]. </p><p>The realization that the rich vascular bed localized under the tongue could serve as a novel approach for allergen delivery led to the development of rapidly dissolving tablets<strong> </strong>that could efficiently be taken-up, processed by local antigen presenting cells, and carried to regional lymph nodes for effective immunization through downregulation of mucosal mast cells, induction of blocking antibody, and activation of T regulatory cells [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/362.html" rel="external">"Allergen immunotherapy for allergic disease: Therapeutic mechanisms"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">AVAILABILITY</span><span class="headingEndMark"> — </span>In the United States, SLIT-tablets are the only form of sublingual aeroallergen immunotherapy that is approved by the US Food and Drug Administration (FDA). In the United States, grass pollen, ragweed pollen, and house dust mite (HDM) tablets are available. In Canada and Europe, a tree tablet has received approval, and in Japan, a cedar tablet is available. Availability of various SLIT-tablet products around the world is shown in the table  (<a class="graphic graphic_table graphicRef120886" href="/d/graphic/120886.html" rel="external">table 1</a>). </p><p>In contrast, SLIT-drops (aqueous/liquid extracts) are not approved by the US FDA; however, they are increasingly being used off-label by allergists, otolaryngologists, and other physicians caring for allergic patients, and they are approved by regulatory bodies in other countries.</p><p class="headingAnchor" id="H2724624222"><span class="h1">ADVANTAGES AND DISADVANTAGES OF SLIT</span><span class="headingEndMark"> — </span>There are several potential advantages of SLIT compared with subcutaneous immunotherapy (SCIT):</p><p class="bulletIndent1"><span class="glyph">●</span>SLIT is safer, with fewer systemic allergic reactions than SCIT. (See <a class="local">'Rare anaphylaxis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SLIT is more comfortable for patients since allergens are ingested rather than injected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SLIT is more convenient for patients and clinicians because therapy is self-administered by the patient (or caregiver) at home.</p><p></p><p>The disadvantages of SLIT include:</p><p class="bulletIndent1"><span class="glyph">●</span>Benefit is reliant on consistent patient self-administration. Patients who regularly miss doses may not have satisfactory results. (See <a class="local">'Compliance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient education will be required to ensure that it is carried out safely and effectively. As an example, patients will require education about how to resume therapy after missed doses. (See <a class="local">'Patient education'</a> below.)</p><p></p><p>The relative efficacies of SLIT and SCIT are reviewed below. (See <a class="local">'Efficacy compared with SCIT'</a> below.)</p><p class="headingAnchor" id="H3026036068"><span class="h1">PATIENT SELECTION</span></p><p class="headingAnchor" id="H505012284"><span class="h2">Indications</span><span class="headingEndMark"> — </span>SLIT-tablet immunotherapy is indicated for the treatment of allergic rhinitis (with or without conjunctivitis) induced by the allergen contained in the product. The approved age ranges differ somewhat among the products, with grass and ragweed pollen SLIT-tablets approved for use in children and all are approved through age 65  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). Because patients are most often treated with a single type of allergen, SLIT is most appropriate for patients in whom one allergen seems to account for the majority of their symptoms. However, published data have shown the ability to sequentially administer grass and ragweed SLIT-tablets, as discussed below. (See <a class="local">'Polysensitized patients'</a> below.)</p><p>The decision to initiate allergen immunotherapy should be based upon a clinical evaluation and physical examination of the patient, complemented by appropriate in vivo or in vitro testing to identify specific allergen sensitivity to the relevant allergen(s), and a detailed discussion with the patient of goals, risks versus benefits, and long-term commitment to the treatment plan. Because SLIT involves long-term daily therapy that is self-administered, it requires a commitment by the patient or caregiver to help maximize compliance. Studies of compliance are reviewed below. (See <a class="local">'Compliance'</a> below.)</p><p class="headingAnchor" id="H278615958"><span class="h3">Safety in patients with asthma</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate asthma</strong> – Trials examining the safety and efficacy of SLIT in patients with rhinoconjunctivitis and concomitant asthma have mostly included patients with mild or intermittent asthma who only required bronchodilators or low-dose daily inhaled corticosteroids. These studies have consistently demonstrated that SLIT is safe in this population [<a href="#rid8">8-20</a>]. Fewer studies have included patients with moderate-persistent asthma [<a href="#rid21">21-24</a>]. These have also shown that SLIT is well tolerated. As an example, in a trial of 834 patients with allergic rhinoconjunctivitis and asthma that was not well controlled on inhaled corticosteroids alone or in combination with a long-acting beta agonist, only one possibly treatment-related moderate asthma exacerbation was observed [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe asthma</strong> – SLIT has not been sufficiently studied in patients with severe asthma, although the limited data that are available are reassuring [<a href="#rid24">24</a>]. Accordingly, all SLIT-tablet products available in the United States and Canada are labeled as contraindicated in patients with severe, unstable, or uncontrolled asthma  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). </p><p></p><p>Studies evaluating the benefit of SLIT on asthma symptoms and medication use are described below. (See <a class="local">'Impact on asthma'</a> below.)</p><p class="headingAnchor" id="H3512547804"><span class="h3">Use in pregnancy</span><span class="headingEndMark"> — </span>Published data addressing the safety of SLIT in pregnancy are lacking. However, reports of adverse outcomes or fetal harm have not emerged despite decades of use in various countries. European manufacturers suggest an approach similar to the one used for injection immunotherapy (ie, that treatment not be initiated in a pregnant patient, but if a woman becomes pregnant during treatment, therapy could be continued provided the patient has not had significant allergic reactions to therapy in the past).</p><p class="headingAnchor" id="H2686701533"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>SLIT-tablets are labeled as contraindicated in patients with any of the following conditions  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>) [<a href="#rid25">25-27</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Asthma that is severe, unstable, or uncontrolled.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of eosinophilic esophagitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of any severe systemic reaction or severe local reaction after taking SLIT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity to any of the inactive ingredients  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). Some tablets contain fish-derived gelatin, although this been shown to be tolerated by the vast majority of fish-allergic patients [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H1874730996"><span class="h2">Pre-administration testing</span><span class="headingEndMark"> — </span>Sensitization to the relative allergen should be confirmed by positive skin test or in vitro testing for allergen-specific immunoglobulin E (IgE) antibodies. </p><p class="headingAnchor" id="H660824433"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>Patients should <strong>discontinue SLIT therapy temporarily</strong> if any of the following occur:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient develops oral inflammation (eg, thrush, mouth ulcers, oral lichen planus) or oral wounds (eg, following dental surgery or tooth extraction). Once the oral mucosa is completely healed, therapy can be resumed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with asthma develops an asthma exacerbation. Once asthma is under control again, the patient should be reassessed to determine if it is appropriate to continue treatment.</p><p></p><p>Patients should be instructed not to take extra doses to "catch up" if they have had gaps in treatment. This may be particularly important at times when allergic rhinitis symptoms are severe.</p><p class="headingAnchor" id="H2783219594"><span class="h2">Polysensitized patients</span><span class="headingEndMark"> — </span>The most compelling data for use of SLIT are in the monosensitized pediatric or adult patient with seasonal allergic rhinoconjunctivitis with or without mild asthma. Nearly all of the high-quality studies available have shown benefit in this context. However, the typical patient in North America is sensitized to multiple aeroallergens. House dust mite (HDM) SLIT-tablet studies have shown significant symptom improvement in patients regardless of sensitization status [<a href="#rid29">29,30</a>]. A grass study likewise demonstrated similar clinical improvement in grass-allergic patients irrespective of their polysensitivity [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of SLIT on unrelated allergens</strong> – The "bystander effect" is a term used in immunotherapy research to describe improvement in allergic symptoms caused by allergen A (eg, grass), which results from immunotherapy with an unrelated, nonhomologous allergen B (eg, ragweed). A small number of studies have directly evaluated subjects for this and have not found an appreciable effect, indicating that the benefits of immunotherapy are specific to the allergen being administered. For example, a study of immunotherapy with Timothy grass SLIT tablets showed no benefit on allergic rhinoconjunctivitis caused by birch tree pollen, two nonhomologous pollens [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of SLIT on related allergens</strong> – Immunotherapy with allergen A may result in improvement in symptoms caused by allergen B if the two allergens share homologous proteins. For example, in a study of birch tree SLIT-tablets, symptoms related to exposure to oak tree pollen were also reduced in patients allergic to both, reflecting that the two pollens share homologous proteins [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of treating just one of the patient's allergies</strong> – Whether it is preferable or necessary to include all the allergens to which the patient is sensitized in their immunotherapy or just a single allergen that seems to be responsible for most of the patient's symptoms is an area of controversy in both SLIT and subcutaneous immunotherapy (SCIT). The data in SLIT are mixed. A post-hoc analysis of data from six randomized trials of grass pollen tablet immunotherapy, including 1871 adults and children, found no difference in the benefit reported by patients who were monosensitized to grass and those who were polysensitized to grass and other allergens during the grass pollen season [<a href="#rid31">31</a>]. In another study, 54 grass-allergic patients were randomized to monotherapy with Timothy extract, Timothy extract plus nine additional unstandardized pollen extracts, or placebo [<a href="#rid34">34</a>]. A modest positive trend was observed in clinical parameters in the multiple pollens group, which did not reach clinical significance. (See  <a class="medical medical_review" href="/d/html/13527.html" rel="external">"SCIT: Preparation of allergen extracts for therapeutic use", section on 'Multiple allergen immunotherapy extracts'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment with multiple SLIT tablets</strong> – The administration of two SLIT tablets simultaneously appears to be well tolerated. In an open-label six-week study, 102 adults allergic to both grass and ragweed pollens received both types of SLIT-tablets in combination to assess tolerability [<a href="#rid35">35</a>]. The respective tablets were each given for two weeks sequentially, followed by simultaneous administration of both tablets five minutes apart for the final two weeks. Another approach is to give one type of tablet in the morning and one in the evening. Treatment was generally well tolerated, with less than five percent of patients discontinuing treatment due to adverse effects. This study provides reassurance that in patients allergic to two pollens, immunotherapy with both tablets may be accomplished with a sequential dosing regimen. Further studies, especially combining pollens and HDM, are needed to assure that multiple tablets can be safely administered. </p><p></p><p class="headingAnchor" id="H1587334234"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>SLIT should be prescribed and initiated by clinicians with expertise in allergy to ensure the optimal selection of patients and allergens. The performance and interpretation of skin test results and the interpretation of in vitro testing both require experience and clinical judgement. The small number of studies that have evaluated the use of SLIT in primary care settings have had disappointing results [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H2870486984"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H1566989534"><span class="h2">Oral and pharyngeal adverse effects</span><span class="headingEndMark"> — </span>The most common adverse effects of SLIT are oral pruritus, ear pruritus, throat irritation, and swelling of the lips, tongue, and pharynx. A smaller percentage of patients may also experience edema of the tongue, uvula, lips, or throat that may occasionally require <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid13">13,38,39</a>]. In clinical trials, 4 to 7 percent of patients dropped out because of adverse effects [<a href="#rid23">23,29,39-41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral mucosal pruritus and irritation</strong> – These self-limited local reactions typically occur with the first dose of treatment and last 10 to 60 minutes. Symptoms tend to lessen in duration with continued therapy and resolve in the majority of patients within one to two weeks. Pollen SLIT-tablets induced oropharyngeal itching/irritation in between 10 and 40 percent of subjects in clinical trials [<a href="#rid42">42,43</a>]. These adverse effects were more pronounced in house dust mite (HDM) studies, in which up to 50 percent of patients initially experienced similar types of mild-to-moderate local reactions [<a href="#rid44">44-46</a>]. However, it should be recognized that this higher percentage of adverse events in the HDM clinical trials is reflective of a change in reporting adverse events by the regulatory agency to that of solicited rather than a true difference in the rate of occurrence. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient angioedema </strong>– Transient angioedema of the sublingual tissues, tongue or oropharynx occurs in 6 to 11 percent of study subjects with pollens, and up to 14 percent with HDM [<a href="#rid46">46</a>]. It is described as a swelling under the tongue at the site of tablet application and typically resolves within 5 to 10 minutes. This adverse effect tends not to appear with first dosing but rather is most likely to be observed at the end of the first week. It is self-limited in most patients, both with respect to severity and duration over the ensuing weeks of treatment.</p><p></p><p class="bulletIndent1">In patients with persistence or worsening of oropharyngeal adverse effects and particularly in those patients experiencing more severe complexity (with laryngeal edema/obstruction), <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> may be indicated, and follow-up with the clinician is necessary to ascertain whether SLIT-tablet therapy should be continued [<a href="#rid10">10,11,47-49</a>].</p><p></p><p class="headingAnchor" id="H2436085363"><span class="h2">Rare anaphylaxis</span><span class="headingEndMark"> — </span>A small number of cases of anaphylaxis have been reported in patients receiving sublingual drops, a form of immunotherapy that is not approved in the United States by the US Food and Drug Administration (FDA) [<a href="#rid50">50-53</a>]. No longitudinal surveillance data have been reported to date for SLIT-tablets; therefore, only limited FDA-reported and clinical trial data can be reviewed. Data from 29 American clinical trials of SLIT-tablets revealed only two systemic reactions (none with airway compromise) and <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> use was 0.2 percent [<a href="#rid54">54</a>]. However, because of the small risk of anaphylaxis, the manufacturers of the SLIT-tablet products available in the United States recommend that patients should be prescribed self-injectable epinephrine and instructed in its proper use [<a href="#rid25">25-27</a>]. There have been no fatalities reported to date with SLIT-tablets (versus seven fatalities with SCIT during the 2015 to 2017 surveillance period) [<a href="#rid54">54,55</a>].</p><p class="headingAnchor" id="H440575780"><span class="h2">Eosinophilic esophagitis</span><span class="headingEndMark"> — </span>An association has been reported between eosinophilic esophagitis and SLIT, as well as with oral immunotherapy with food allergens [<a href="#rid56">56-59</a>]. However, reports are rare, with only six cases reported in the world's literature as of 2019 [<a href="#rid60">60</a>]. SLIT should be discontinued in patients who develop severe or persistent gastroesophageal symptoms (including dysphagia or chest pain), and the diagnosis of eosinophilic esophagitis should be considered. Pre-existing eosinophilic esophagitis or a history of this disorder is a contraindication to the use of SLIT  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2243.html" rel="external">"Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H2643464038"><span class="h2">Initiating therapy</span><span class="headingEndMark"> — </span>SLIT-tablets are rapidly dissolving tablets that are held under the tongue until completely dissolved. SLIT-tablet therapy is initiated with a full dose in most cases. One grass pollen product stipulates a short escalation in dose when used in children 10 to 17 years of age  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). The first dose is given under medical supervision, and patients should be observed for at least 30 minutes for any signs of an allergic reaction. Subsequent doses are self-administered once daily by the patient or caregiver at home. </p><p>Hands should be clean and completely dry before handling the tablets. The tablet is placed under the tongue and held there for at least one minute or until fully dissolved, after which the patient should not swallow for at least one minute and not ingest food or beverage for five minutes. </p><p>Premedication with H1 antihistamines is not suggested in the product inserts of SLIT-tablets, and we do not specifically instruct patients to take an antihistamine prior to initiating sublingual immunotherapy. However, it is recommended that patients continue their usual medications when they are beginning SLIT-tablets, including antihistamines and any other medications taken regularly for allergic rhinoconjunctivitis.</p><p class="headingAnchor" id="H766503708"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>The majority of United States clinical studies have defined a single optimal dose based on prior dose-ranging safety studies [<a href="#rid61">61-65</a>]. In general, SLIT requires higher doses than subcutaneous immunotherapy (SCIT). In some SLIT studies, the daily dose of allergenic protein in micrograms is equivalent to the dose given every two to four weeks in SCIT. The cumulative amount of allergen administered in the course of one year is up to 30 times greater with SLIT-tablets compared with SCIT [<a href="#rid66">66</a>]. Possible reasons for the higher dose requirements with SLIT may include loss of allergen from the sublingual site, processing differences of antigen uptake by lymphoid tissue within Waldeyer's Ring versus gut-associated lymphoid tissue (GALT), and other undefined mechanisms. </p><p class="headingAnchor" id="H4178984591"><span class="h2">Timing relative to pollen seasons</span><span class="headingEndMark"> — </span>SLIT-tablet therapy for pollen allergy is initiated three to four months prior to the allergen season (called "preseasonal treatment"), because clinical benefit begins within three to four months. Daily therapy is then maintained through the end of the pollen season. SLIT can also be safely started during pollen season (called "co-seasonal treatment") [<a href="#rid67">67</a>]. Continuous year-round SLIT is another option for pollen allergy, although in open-label studies of grass pollen SLIT, this did not appear to be superior to preseasonal treatment after the first year [<a href="#rid68">68,69</a>]. However, the best approach is not clear, since the studies that showed persistent benefit two years after completion of a three-year course of therapy used continuous year-round treatment [<a href="#rid70">70</a>]. (See <a class="local">'Duration of therapy'</a> below.)</p><p>House dust mite (HDM) SLIT-tablets can be safely started at any time of year, including during pollen seasons in patients who are also sensitized to pollens [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H19446926"><span class="h2">Labeling of specific products</span><span class="headingEndMark"> — </span>Available products are shown in the table  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). Each has unique dosing units. All are approved for adults up to the age of 65 years. The grass and ragweed tablets are US Food and Drug Administration (FDA)-approved for children, whereas the HDM tablet is under study for this age group. Excipients should be reviewed to ensure that the patient has no history of allergies to these substances. Some tablets contain fish-derived gelatin, which is tolerated by the majority of fish-allergic patients [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H31842583"><span class="h3">5-grass sublingual tablet</span><span class="headingEndMark"> — </span>The 5-grass pollen sublingual tablet (Oralair) is indicated for the treatment of grass pollen-induced allergic rhinitis (with or without conjunctivitis) in patients 5 to 65 years of age  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). Sensitization to any of the 5-grass species contained in the tablet (Timothy, Orchard, Perennial Rye, Kentucky Blue, Sweet Vernal) should be confirmed by positive skin test or in vitro testing for pollen-specific immunoglobulin E (IgE) antibodies to <strong>any</strong> of the 5-grass species contained in the tablet.</p><p class="bulletIndent1"><span class="glyph">●</span>Dosing is expressed in index of reactivity (IR) units. For children 10 to 17 years of age, a two-day dose escalation is stipulated (100 IR tablet on day 1, two 100 IR tablets on day 2, one 300 IR tablet daily thereafter, if tolerated). Patients 18 years and older start with the full 300 IR tablet, which contains approximately 25 mcg/mL of group 5 major allergens. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment should be started four months (16 weeks) prior to the expected onset of the respective grass season and continued through the grass season. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common adverse effects were oral pruritus, throat irritation, ear pruritus, and mouth edema (25, 22, 8, and 8 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oralair was not studied in patients with moderate or severe asthma or patients requiring daily controller therapy [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H88937801"><span class="h3">Timothy grass pollen sublingual tablet</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="95239" href="/d/drug information/95239.html" rel="external">Timothy grass pollen sublingual tablet</a> (Grastek) is indicated for the treatment of grass pollen-induced allergic rhinitis (with or without conjunctivitis) in patients 5 to 65 years of age [<a href="#rid26">26</a>]. Prior to considering this therapy, allergy to Timothy or to a cross-reactive temperate grass species (Sweet Vernal, Orchard, Perennial Rye, Kentucky Blue/June, Meadow Fescue, or Redtop) should be confirmed by positive skin test or in vitro testing for pollen-specific IgE to Timothy grass or to one of the cross-reactive grass pollens. Patients living in geographic areas with other grass species, such as Bermuda or Bahia, which do not cross-react with Timothy and other temperate grasses, may not have as complete a therapeutic response to the Timothy grass pollen sublingual tablet, depending on the degree to which they are sensitive to these other grasses. In addition, there is some evidence that although grass allergens are highly homologous across species, individual allergens may be differentially recognized by T cells, and therefore, a 5-grass tablet may provide a broader array of clinically relevant epitopes [<a href="#rid72">72</a>]. However, there is no evidence that the 5-grass tablet provides superior efficacy over the Timothy grass pollen sublingual tablet.</p><p class="bulletIndent1"><span class="glyph">●</span>Dosing is expressed in bioequivalent allergy units (BAUs) of Timothy grass pollen. Each tablet contains 2800 BAUs of Timothy grass pollen (approximately 15 mcg Phl p 5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment should be started three months (12 weeks) prior to the expected onset of the respective grass season and continued through the grass season. It may be taken throughout the year and for three consecutive years, although the optimal schedule of treatment has not been determined. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common adverse effects were oral pruritus, throat irritation, ear pruritus, and mouth edema (27, 23, 13, and 11 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grastek was not studied in patients with moderate or severe asthma or those requiring daily controller therapy [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H733084545"><span class="h3">Short ragweed pollen sublingual tablet</span><span class="headingEndMark"> — </span>The short <a class="drug drug_general" data-topicid="94962" href="/d/drug information/94962.html" rel="external">ragweed pollen sublingual tablet</a> (Ragwitek) is indicated for the treatment of short ragweed pollen-induced allergic rhinitis (with or without conjunctivitis) in patients 5 to 65 years of age  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). Allergy to short ragweed should be confirmed by positive skin test or in vitro testing for specific IgE to short ragweed pollen [<a href="#rid27">27</a>]. It should be noted that there is extensive cross-reactivity among common ragweed species (ie, short, giant, false, and western) [<a href="#rid73">73-76</a>]. There is a reasonable assumption that the available product would be useful for treating allergy caused by any ragweed species. </p><p class="bulletIndent1"><span class="glyph">●</span>Dosing is expressed in units of major allergen. Each tablet contains 12 Amb a 1 units of short ragweed pollen (approximately 12 mcg Amb a 1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment should be started at least three months (12 weeks) prior to the expected onset of the respective ragweed season and continued through the ragweed season.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common adverse effects were throat irritation, oral pruritus, ear pruritus, and oral paresthesias (17, 11, 10, and 10 percent, respectively) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The short <a class="drug drug_general" data-topicid="94962" href="/d/drug information/94962.html" rel="external">ragweed pollen sublingual tablet</a> is labeled as contraindicated in patients with severe, unstable, or uncontrolled asthma; a history of any severe systemic allergic reaction; a history of any severe local reaction after taking SLIT; a history of eosinophilic esophagitis; or hypersensitivity to any of the inactive ingredients.</p><p></p><p class="headingAnchor" id="H2005385416"><span class="h3">Dust mite sublingual tablet</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="112242" href="/d/drug information/112242.html" rel="external">house dust mite sublingual tablet</a> (Odactra) is indicated for the treatment of dust mite-induced allergic rhinitis (with or without conjunctivitis) in patients 12 to 65 years of age  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>) [<a href="#rid77">77</a>]. Allergy to HDM should be confirmed by positive skin test to licensed HDM allergen extracts or in vitro testing for specific IgE to <em>Dermatophagoides farinae</em> or <em>D. pteronyssinus</em>. </p><p class="bulletIndent1"><span class="glyph">●</span>Dosing is expressed in standardized-quality house dust mite (SQ-HDM) units of HDM allergen. Each tablet contains 12 SQ-HDM units of HDM allergen.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common adverse effects were oral pruritus, ear pruritus, and throat irritation (47, 40, and 36 percent, respectively) [<a href="#rid77">77</a>]. The rates of adverse reactions in this study were higher than in other studies, probably because the study design actively solicited symptoms of local reactions from patients on their electronic daily diary cards, rather than relying on spontaneously reported symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The HDM sublingual tablet is labeled as contraindicated in patients with severe, unstable, or uncontrolled asthma; a history of any severe systemic reaction or severe local reaction after taking SLIT; a history of eosinophilic esophagitis; or hypersensitivity to any of the inactive ingredients. </p><p></p><p class="headingAnchor" id="H11"><span class="h1">EFFICACY FOR ALLERGIC RHINOCONJUNCTIVITIS</span><span class="headingEndMark"> — </span>The efficacy and safety of SLIT has been demonstrated in a number of properly designed European trials for both children and adults with allergic rhinitis. </p><p class="headingAnchor" id="H2444027180"><span class="h2">Outcome measures for immunotherapy trials</span><span class="headingEndMark"> — </span>There have been efforts to standardize the outcome measures in trials of immunotherapy for respiratory allergy, to use validated tools that can be compared across studies, and to reach consensus about what degree of therapeutic benefit should be considered clinically meaningful [<a href="#rid5">5,78,79</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In 2012, the World Allergy Organization (WAO) proposed that a 20 percent mean reduction in total combined score (TCS) compared with placebo be considered the minimum change that corresponds to a clinically meaningful benefit [<a href="#rid80">80</a>]. The decision as to what represents a sufficient therapeutic effect must be tempered by the risk:benefit ratio of the therapeutic agent. Traditionally, the bar has been set somewhat higher for a treatment such as injection immunotherapy, where the risks (ie, anaphylaxis induced by the injections) were perceived as relatively significant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For an allergen immunotherapy therapeutic to be approved by the US Food and Drug Administration (FDA), two statistical efficacy criteria must be met: a) Criterion 1 (point estimate): a difference of 15 percent in the TCS between active treatment and placebo must be demonstrated; b) Criterion 2 (confidence interval): a lower bound of the 95 percent confidence interval of that difference demonstrating at least a 10 percent separation between the two groups must be demonstrated. These statistical tests were selected after rigorous internal evaluation by the agency and have been mandated to identify and define a statistically significant and clinically meaningful therapeutic effect more clearly when comparing allergen immunotherapy with placebo.</p><p></p><p class="headingAnchor" id="H1031930695"><span class="h3">Efficacy compared with pharmacotherapy</span><span class="headingEndMark"> — </span>Based on indirect comparisons, the efficacy of SLIT-tablets for seasonal allergic rhinitis to pollen appears to be similar to that of corticosteroid nasal sprays but superior to either antihistamines or <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a> [<a href="#rid81">81</a>], while the efficacy of house dust mite (HDM) SLIT-tablets appears to be superior to any single pharmacologic therapy for perennial allergic rhinitis [<a href="#rid82">82</a>]. </p><p>A 2016 study that compared pooled efficacy data from 10 randomized trials of SLIT-tablets (for treatment of seasonal or perennial allergic rhinitis) with data from studies of pharmacotherapy found that SLIT-tablet treatment resulted in an overall improvement in total nasal symptom scores of 16 to 17 percent relative to placebo [<a href="#rid82">82</a>]. </p><p>By comparison, trials of <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> furoate nasal spray, <a class="drug drug_general" data-topicid="8472" href="/d/drug information/8472.html" rel="external">desloratadine</a>, and <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>, all at full strength, resulted in improvements in total nasal symptom scores of 22, 9, and 5 percent, respectively, for seasonal allergic rhinitis and 11, 5, and 4 percent, respectively, for perennial allergic rhinitis. Limitations of this analysis included the fact that most SLIT studies allowed for use of rescue medications, while trials of pharmacotherapy generally did not, which would potentially underestimate the effect of SLIT. However, this study design also provides evidence for the additive effects of SLIT beyond pharmacotherapy. Another limitation of the analysis was the lack of trials employing combinations of pharmacotherapies, which would more closely simulate "maximal medical therapy." </p><p class="headingAnchor" id="H3836394435"><span class="h3">Efficacy compared with SCIT</span><span class="headingEndMark"> — </span>A 2021 network meta-analysis (NMA) of 26 randomized double-blind clinical trials reached a similar conclusion [<a href="#rid83">83</a>]. Clinical symptoms and medication improvement was ascertained for each type of immunotherapy (directly for each agent against placebo, and indirectly for comparisons between types of therapy), with the NMA providing data to suggest that subcutaneous immunotherapy (SCIT) was more effective than SLIT-tablets and SLIT-drops. </p><p>A small number of trials have directly compared SLIT and SCIT [<a href="#rid66">66,84-91</a>]. Three randomized trials involved head-to-head, double-dummy protocols [<a href="#rid66">66,84,85</a>]. Although each study had methodologic issues and small numbers of patients, two of three found SCIT to be at least somewhat more effective than SLIT.</p><p class="headingAnchor" id="H2008095864"><span class="h3">Efficacy compared with placebo</span><span class="headingEndMark"> — </span>In multiple randomized trials, SLIT tablets have been shown to reduce symptom scores and medication requirements in patients with allergic rhinoconjunctivitis.</p><p>In a 2017 systematic review that included 41 randomized trials and approximately 4500 adults and children receiving active SLIT treatment (tablets or drops) or placebo, treatment with SLIT resulted in a reduction in symptom scores (standardized mean difference [SMD] –0.48 [95% CI –0.61 to –0.36]) and in medication requirements (SMD –0.31 [95% CI –0.44 to –0.18]) [<a href="#rid92">92</a>]. Nine studies reported on TCS, which were also reduced (SMD –0.47 [95% CI –0.81 to –0.12]). Most studies involved treatment with single pollens (most commonly grass) or HDM preparations at a range of doses. Effects on quality of life could not be assessed because a variety of different measurements were used. There was some evidence of publication bias. However, this systematic review did not include subsequent important studies of HDM-SLIT. (See <a class="local">'House dust mite tablet'</a> below.)  </p><p class="headingAnchor" id="H229498601"><span class="h3">Specific products</span></p><p class="headingAnchor" id="H26391459"><span class="h4">Grass tablet</span><span class="headingEndMark"> — </span>A 2015 systematic review and meta-analysis of all randomized trials (through 2014) evaluating grass pollen SLIT-tablet immunotherapy found a treatment benefit on symptom score (SMD –0.28; 95% CI –0.37 to –0.19) and medication score (SMD –0.24; 95% CI –0.31 to –0.17) [<a href="#rid93">93</a>]. Representative studies are discussed below.</p><p class="headingAnchor" id="H6514669"><span class="h5">Timothy grass pollen tablet</span><span class="headingEndMark"> — </span>European and North American studies with the Timothy grass pollen SLIT-tablet have demonstrated clinical benefit in grass-allergic subjects [<a href="#rid44">44,47,48,61,94,95</a>]. Pivotal trials are described below.</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 634 European adults with grass-induced seasonal allergic rhinoconjunctivitis, subjects received once-daily treatment with a Timothy SLIT-tablet (Grazax) containing 15 mcg Phl p 5 or placebo [<a href="#rid44">44</a>]. Treatment was initiated 16 weeks preseason and continued during the season within a study design that was extended to incorporate a two-year maintenance phase and a two-year follow-up after discontinuation of therapy (ie, five years in total) [<a href="#rid44">44,96</a>]. (See <a class="local">'Duration of therapy'</a> below.) </p><p></p><p class="bulletIndent1">Mean rhinoconjunctivitis symptom scores and medication scores improved 30 and 38 percent, respectively, compared with placebo. There were also significant increases in the number of well days (53 versus 44 percent) and improvements in quality of life in the treatment group. After the first year, the study was continued, demonstrating that three years of continuous daily therapy conferred sustained benefit over the three years of treatment (ie, reductions in total rhinoconjunctivitis combined scores of 33; 41; and 36 percent over the three years), with a persistence of clinical benefit in the fourth and fifth grass seasons (off treatment) (reductions of 27 and 23 percent, respectively).</p><p></p><p class="bulletIndent1">The first year of this study of the Timothy grass product was accepted by the US FDA as pivotal data for approval, and the complete data set of the study was reviewed and accepted as the basis for the multiple year approval of the product in grass-allergic patients [<a href="#rid96">96</a>]. Data for maintaining sustained effectiveness beyond this timeframe have not been established. (See <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A European study in grass-allergic children demonstrated similar efficacy and safety [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>American trials of Timothy grass pollen SLIT-tablets used a dose of 15 mcg Phl p 5 in both adults and children [<a href="#rid47">47,48</a>]. These trials were large (300 to 400 patients each), and 85 to 90 percent of patients were sensitized to multiple allergens in addition to grass pollen. The primary endpoint, the combined daily symptom plus medication score, improved (was reduced) by 20 percent (difference versus placebo –1.31 [95% CI –2.8 to –0.36]) in adults and 26 percent (difference versus placebo –1.63 [95% CI –2.60 to –0.66]) in adolescents and children. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the largest United States SLIT study of 1501 children and adults, the <a class="drug drug_general" data-topicid="95239" href="/d/drug information/95239.html" rel="external">Timothy grass pollen sublingual tablet</a> showed efficacy in both primary and secondary outcomes similar to that demonstrated in the positive trials performed earlier [<a href="#rid94">94</a>]. </p><p></p><p class="headingAnchor" id="H14"><span class="h5">Multiple grass pollen tablet</span><span class="headingEndMark"> — </span>There are a number of high quality studies with the 5-grass pollen tablet in both children and adults [<a href="#rid40">40,97-101</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, placebo-controlled trial performed on 473 American adults used the 300 index of reactivity (IR) dose 5-grass pollen sublingual tablet [<a href="#rid40">40</a>]. Compared with placebo, active treatment patients showed a 28 percent improvement in the primary efficacy measure of total combined score plus medication score  (<a class="graphic graphic_figure graphicRef94991" href="/d/graphic/94991.html" rel="external">figure 1</a>). Similar improvements were observed in the secondary outcome measurements, including daily rhinitis total symptom score (23 percent), daily rhinitis rescue medication score (46 percent), overall rhinoconjunctivitis quality of life questionnaire score, and respective individual symptom scores (except nasal itch). </p><p></p><p class="headingAnchor" id="H23587747"><span class="h4">Ragweed tablet</span></p><p class="bulletIndent1"><span class="glyph">●</span>In a multinational dose-ranging trial performed in 784 adults with allergic rhinitis caused by ragweed (with or without conjunctivitis or mild asthma), subjects were randomly assigned to placebo or to three different doses of ragweed SLIT-tablet (containing 1.5, 6, or 12 units of Amb a 1 protein, where 1 unit is approximately equal to 1 mcg) [<a href="#rid10">10</a>]. Therapy was initiated four months prior to the ragweed pollen season and continued for one year (for safety monitoring). The primary endpoint was the total combined symptom/medication score (TCS) during peak ragweed season. The 6 and 12 unit tablets reduced TCS by 19 percent (difference versus placebo –1.58 [95% CI –2.8 to –0.36]) and 24 percent (difference versus placebo –2.04 [95% CI –3.30 to –0.79]), respectively  (<a class="graphic graphic_figure graphicRef94992" href="/d/graphic/94992.html" rel="external">figure 2</a>). Only the 12 Amb a 1 U dose met the 95 percent lower bounds of the confidence interval criterion required by the US FDA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the second trial performed in North America, 565 ragweed allergic patients were randomized to two strengths of tablet (6 or 12 units of Amb a 1) or to placebo, and a similar degree of improvement in TCS was demonstrated (21 and 27 percent, respectively) versus placebo during the peak season [<a href="#rid11">11</a>]. </p><p></p><p class="headingAnchor" id="H18871339"><span class="h4">House dust mite tablet</span><span class="headingEndMark"> — </span>Randomized trials have demonstrated the efficacy and safety of HDM SLIT-tablets for the treatment of allergic rhinitis [<a href="#rid21">21,23,29,30,102,103</a>]. The Odactra (ALK) product has received FDA approval. Other products are under review [<a href="#rid104">104</a>]. </p><p>In a representative trial of 1482 subjects (aged ≥12 years) with HDM-induced allergic rhinitis with or without either conjunctivitis and/or asthma, subjects were randomized to one year of daily treatment with a 12 unit standardized-quality HDM (SQ-HDM) SLIT-tablet or placebo [<a href="#rid29">29</a>]. The primary endpoint was the average total combined rhinitis score, which was defined as the daily rhinitis symptom score plus rhinitis daily medication score, during the last two months of treatment. Active treatment improved the total combined rhinitis score by 17 percent (95% CI 10-25 percent) versus placebo and was well tolerated.</p><p>Studies of HDM SLIT in patients with asthma are discussed below. (See <a class="local">'Impact on asthma'</a> below.)</p><p class="headingAnchor" id="H2798864285"><span class="h4">Birch tree tablet</span><span class="headingEndMark"> — </span>A <a class="drug drug_general" data-topicid="130043" href="/d/drug information/130043.html" rel="external">white birch sublingual tablet</a>, which treats allergic rhinitis caused by birch, alder, hazel, and oak pollens, has been approved in Europe (2019) and in Canada (2020)  (<a class="graphic graphic_table graphicRef120886" href="/d/graphic/120886.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial using the Vienna environmental exposure chambers (VEEC), 219 European patients with birch pollen-related allergic rhinoconjunctivitis received three different strengths of birch pollen SLIT-tablets for 24 weeks, followed by exposure to birch pollen in a chamber challenge, and then to oak pollen, which shares homologous proteins with birch [<a href="#rid33">33</a>]. The highest dose most effectively reduced symptoms to both pollens in the VEEC, with effects apparent at 16 weeks of treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 634 birch and oak allergic patients treated with the sublingual birch homologous tree pollen tablet, significant improvements in the TCS (25 percent), daily symptom score (22 percent), and daily medication score (32 percent) compared with placebo were observed over the course of the oak tree pollen season. In addition, the immunizing regimen induced oak-specific protective antibody. This natural exposure seasonal trial demonstrated that the tree pollen tablet provided meaningful clinical improvement not only against birch allergy but also in oak-sensitive patients who share Bet v 1 cross-reactivity [<a href="#rid105">105</a>]. </p><p></p><p class="headingAnchor" id="H2608296411"><span class="h4">Japanese red cedar tablet</span><span class="headingEndMark"> — </span>Japanese red cedar is the predominant seasonal allergen in Japan and is recognized as a major cause of allergic rhinoconjunctivitis in the Japanese population. The 5000 JAU (allergy unit) SLIT-tablet received approval from the Japanese Ministry of Health Labor and Welfare in 2017 for patients aged 5 to 64 years. </p><p>In a trial of 1042 patients with Japanese cedar pollinosis, subjects were randomized to three different dosing regimens of active drug (2000, 5000, 10,000 JAU) or placebo. The primary clinical endpoint of Total Nasal Symptom and Medication Score was reduced by 21, 32, and 32 percent respectively versus placebo. Both the 5000 and 10,000 JAU regimens were comparable and statistically superior to the 2000 JAU dose, which served as the basis for 5000 JAU being selected as the optimal treatment dose [<a href="#rid106">106,107</a>].</p><p class="headingAnchor" id="H2017180783"><span class="h1">IMPACT ON ASTHMA</span></p><p class="headingAnchor" id="H1218629937"><span class="h2">Improvement in asthma symptoms</span><span class="headingEndMark"> — </span>SLIT has been shown in randomized trials to be safe for patients with concomitant mild-to-moderate asthma, and most studies have reported improvements in asthma symptom scores and medication use, while a smaller number have not. However, improvement in several patient-important asthma outcomes has not been conclusively demonstrated. In a 2020 systematic review of 66 studies including nearly 8000 children and adults, several patient-important primary outcomes were evaluated: Asthma exacerbations requiring a visit to the emergency department or admission to hospital, validated measures of quality of life, and all-cause serious adverse events [<a href="#rid108">108</a>]. Secondary outcomes were asthma symptom scores, exacerbations requiring systemic glucocorticoids, response to provocation tests, and dose of inhaled glucocorticoids. However, with the exception of all-cause serious adverse events, which were not increased in patients receiving SLIT, these outcomes were not included or commented on in most of the studies, limiting the ability of the review to assess them. Trials that did include relevant outcomes mostly found a trend towards improvement in asthma symptoms.</p><p>In contrast to the systematic review of all types of SLIT, studies in house dust mite (HDM)-induced allergic asthma have provided consistent evidence that treatment improves asthma symptoms [<a href="#rid29">29</a>], reduces the risk of moderate-to-severe asthma exacerbations, nocturnal awakenings, relief medication use, and minimizes deterioration in lung function [<a href="#rid23">23,109</a>]. Based on these data, a 2019 guideline from the European Academy of Allergy and Clinical Immunology (EAACI) and a 2020 update to the Global Initiative for Asthma (GINA) guideline both endorse the use of HDM-SLIT tablets (and HDM subcutaneous immunotherapy [SCIT]) as add-on therapy for patients with mild-to-moderate allergic asthma and HDM allergy to decrease symptoms and medication use [<a href="#rid110">110,111</a>]. The GINA guideline suggests that clinicians "Consider adding HDM SLIT for sensitized patients with allergic rhinitis and an FEV1 &gt;70 percent predicted" [<a href="#rid111">111</a>]. </p><p>In a randomized trial of 39 patients with asthma who received 24 weeks of either HDM-SLIT or placebo in addition to their asthma therapy, HDM-SLIT resulted in increased epithelial cell antiviral responses in vitro, suggesting a potential mechanism by which HDM-SLIT may reduce exacerbations [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H3346648397"><span class="h2">Reduced risk of asthma development</span><span class="headingEndMark"> — </span>Both SCIT and SLIT-tablets appear to reduce the risk of developing asthma, particularly in children [<a href="#rid113">113,114</a>]. </p><p><strong>3</strong></p><p>In a randomized trial, 812 children (5 to 12 years) with grass pollen-allergic rhinoconjunctivitis and without asthma were randomized to three years of treatment with a grass SLIT-tablet or placebo and followed for an additional two years [<a href="#rid113">113</a>]. Treatment with the SLIT-tablet significantly reduced the risk of experiencing asthma symptoms or using asthma medication at the end of trial, during the two-year follow-up, and during the five-year study period (odds ratio [OR] 0.66 [95% CI 0.45-0.97]), corresponding to a relative risk reduction of 29 percent. </p><p>The preventative effects of SCIT on the development of asthma are discussed separately. (See  <a class="medical medical_review" href="/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy", section on 'Preventive effects'</a>.)</p><p class="headingAnchor" id="H3790334"><span class="h1">COMPLIANCE</span><span class="headingEndMark"> — </span>SLIT requires a commitment by the patient to a long-term daily maintenance therapy that is self-administered, and compliance is likely to be lower than that obtained in supervised clinical trials [<a href="#rid115">115</a>]. Past surveillance studies showed poor real-world compliance with all forms of allergen immunotherapy, with up to one-half of patients discontinuing therapy, and studies in both children and adults indicate that long-term compliance with SLIT is similarly low [<a href="#rid116">116-119</a>]. However, frequent follow-up, particularly in the first months of treatment, may encourage patients to remain on therapy. A 2010 study of 300 children (6 to 16 years of age) who received either grass or house dust mite (HDM) sublingual drops or tablets over two years of treatment demonstrated that discontinuation rates were clearly tied to the frequency of follow-up [<a href="#rid120">120</a>]. In patients evaluated in the clinic every 3, 6, and 12 months, the dropout rate was 8, 15, and 29 percent, respectively, at the end of one year and worsened to 10, 18, and 41 percent at the end of two years. Similarly, when looking at prescription refills, a marker of real-world use, SLIT sales decreased to 44, 28, and 13 percent over three years [<a href="#rid116">116</a>].</p><p>A 2018 open-label observational study of adherence in a real-world practice setting in Scandinavia showed 55 percent of their 399 patients (59 percent adults, 41 percent children) completed three years of year-round treatment with the Timothy grass SLIT-tablet, and those patients adhering to the defined protocol (per-protocol) exhibited marked improvement in adherence (year 1: 94 percent; year 2: 93 percent; year 3: 89 percent) [<a href="#rid121">121</a>]. Sixty-five percent of dropouts occurred before completion of the first year of treatment, which again emphasizes the importance of explaining to the patient the expected side effects with SLIT-tablet treatment, the likelihood of adverse effects occurring in the first several weeks but diminishing with continued dosing, and knowing the signs that alert the patient to follow up with the medical office. </p><p>The following measures may help optimize compliance:</p><p class="bulletIndent1"><span class="glyph">●</span>Ensure there is good understanding of the expected benefit and time course of improvement before starting therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clearly explain the adverse effects that are possible and how to handle each of these, including knowing when to call the allergist's office, administer <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, or proceed to an emergency department.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schedule regular follow-up visits to assess progress and problems.</p><p></p><p>Patient information is provided. (See <a class="local">'Information for patients'</a> below.)  </p><p class="headingAnchor" id="H1470782798"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>The optimal duration for a course of SLIT has not been fully defined. Based on available studies reviewed below, we would suggest to grass-allergic patients that if they find the Timothy grass SLIT-tablet helpful after the initial grass season, and the daily regimen was not burdensome to maintain, then the grass literature supports that three years of continuous daily therapy is likely to confer some lasting benefit after treatment is discontinued, and the product is approved for use in this manner [<a href="#rid96">96,98</a>]. However, for house dust mite and other allergen SLIT-tablets, longer-term clinical data are needed to establish the optimal duration of therapy, and in the case of pollens, gain approval for continuous use. </p><p class="bulletIndent1"><span class="glyph">●</span>Three years of continuous daily therapy with the Timothy grass SLIT-tablet conferred benefit over the three years of treatment (ie, reductions in Total Rhinoconjunctivitis Combined Scores of 33, 41, and 36 percent) with sustained symptom control in the fourth and fifth grass seasons (off treatment) (reductions of 27 and 23 percent, respectively) [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, three years of continuous therapy with the Timothy grass SLIT-tablet in 812 children (ages 5 to 12 years) with asthma demonstrated sustained efficacy in the two grass seasons following completion of a three-year period of daily treatment in the GAP study [<a href="#rid113">113</a>]. Treatment reduced the risk of experiencing asthma symptoms or using asthma medications at the trial's end, during the two-year follow-up (off treatment), and over the full five-year course of the study (odds ratio: 0.66).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three years of discontinuous treatment (16 weeks prior to the season, throughout the season, and stopping at the end of the season) was evaluated in a five-year study of the 5-grass SLIT-tablet [<a href="#rid122">122</a>]. Subjects were blinded and maintained symptom diaries during the subsequent fourth and fifth grass pollen seasons. This study also demonstrated clinical benefit across the five grass seasons, although it did not meet the full requirements of the US Food and Drug Administration, and the drug was approved for a seasonal indication only. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast to the three-year studies above, two years of continuous treatment with the Timothy grass SLIT-tablet did not provide sustained benefit. In a nasal provocation study of grass-allergic patients with moderate-to-severe seasonal allergic rhinitis treated continuously for two years, the nasal response to allergen challenge at year 3 (one year off treatment) showed no difference between SLIT and placebo-treated patients, thus suggesting that a minimum of three years of treatment with the SLIT-tablet is necessary to induce longer-term clinical tolerance once treatment is stopped [<a href="#rid123">123</a>]. </p><p></p><p>These studies are consistent with clinical trials of subcutaneous immunotherapy (SCIT) that have been the hallmark studies providing evidence that three years of "maintenance" treatment confers a persistent therapeutic benefit once subcutaneous injections have stopped [<a href="#rid124">124-126</a>]. (See  <a class="medical medical_review" href="/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy", section on 'Persistence of benefit after discontinuation'</a>.)</p><p>Data on other SLIT products are limited. In a randomized trial, one full year of treatment with house dust mite SLIT in patients with moderate-to-severe allergic rhinitis conferred a treatment benefit that persisted through the second year (during which patients were blinded and received no further immunotherapy) [<a href="#rid102">102</a>]. However, longer-term studies are needed. (See <a class="local">'House dust mite tablet'</a> above.)</p><p class="headingAnchor" id="H843438258"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105693.html" rel="external">"Society guideline links: Allergen immunotherapy for the treatment of respiratory allergy"</a>.)</p><p class="headingAnchor" id="H998999406"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_patient" href="/d/html/134429.html" rel="external">"Patient education: Sublingual immunotherapy (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H31103307"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available products</strong> – Sublingual immunotherapy (SLIT) involves the application of allergen to the sublingual tissue. The most consistent benefit has been obtained with SLIT-tablet formulations using rapidly dissolving tablets, which are the only form of SLIT that is approved by the US Food and Drug Administration (FDA). Specific SLIT-tablet products available around the world are shown in the table  (<a class="graphic graphic_table graphicRef120886" href="/d/graphic/120886.html" rel="external">table 1</a>). (See <a class="local">'Availability'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparison to subcutaneous immunotherapy (SCIT)</strong> – The main advantages of SLIT over SCIT are safety (ie, anaphylaxis is rare) and the comfort and convenience of an oral therapy that is self-administered. The main disadvantages of SLIT are that it relies on the patient to self-administer the therapy daily and is slightly less effective than SCIT. (See <a class="local">'Advantages and disadvantages of SLIT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> <strong>and pretreatment testing </strong>– SLIT-tablet immunotherapy is best suited for patients with allergic rhinoconjunctivitis with or without mild-to-moderate controlled asthma, in whom one allergen seems to account for the majority of their symptoms, since patients are treated with one type of tablet at a time. However, studies of sequential administration (eg, pollen tablets during pollen season, followed by dust mite tablets during winter) are ongoing, which may impact future recommendations. Sensitization to the relative allergen should be confirmed by positive skin test or in vitro testing for allergen-specific immunoglobulin E (IgE) antibodies. The approved age ranges differ somewhat among the products, with some pollen SLIT-tablets approved for use in children and most products approved through age 65  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). (See <a class="local">'Patient selection'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> <strong>and adverse effects</strong> – All SLIT-tablets are labeled as contraindicated in patients with severe, unstable, or uncontrolled asthma. Other contraindications include a history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients  (<a class="graphic graphic_table graphicRef95082" href="/d/graphic/95082.html" rel="external">table 2</a>). The most common adverse effect of SLIT-tablet therapy is itching of the mouth, lips, tongue, or ears and mild swelling of the sublingual tissues, which occurs in up to 50 percent of patients at the start of treatment and generally resolves within one to two weeks. Anaphylaxis and eosinophilic esophagitis are rare side effects. (See <a class="local">'Adverse effects'</a> above and <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – SLIT is self-administered by patients (or their caregivers) at home, although the first dose is usually given under medical supervision. For the treatment of rhinitis due to pollen allergy, SLIT should be initiated three to four months before the onset of the relevant pollen season. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy for allergic rhinoconjunctivitis:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The efficacy of SLIT-tablets for seasonal allergic rhinitis to pollens appears to be similar to that of glucocorticoid nasal sprays but superior to antihistamines or <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>, based on indirect comparisons. The efficacy of house dust mite SLIT-tablets appears to be superior to any single pharmacologic therapy. However, SLIT therapy has not been compared to maximal medical therapy using combinations of medications. (See <a class="local">'Efficacy compared with pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SLIT appears to be somewhat less effective than SCIT. (See <a class="local">'Efficacy compared with SCIT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with placebo, SLIT-tablet therapy reduces symptoms of allergic rhinoconjunctivitis between 15 and 30 percent. (See <a class="local">'Efficacy compared with placebo'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on asthma</strong> – Most studies that have included patients with mild-to-moderate asthma have found improvements in asthma symptom scores and medication use. However, improvements in other patient-important asthma outcomes, such as reductions in exacerbations requiring emergency care or oral corticosteroids, have not been demonstrated and few studies have included these outcomes in the study designs. (See <a class="local">'Impact on asthma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compliance </strong>– Compliance with all forms of immunotherapy is relatively low, and this is true of SLIT-tablet therapy as well. Close follow-up in the initial months of treatment can reassure patients experiencing local oral side effects and help them remain compliant until they experience benefit, which typically begins after three to four months. (See <a class="local">'Compliance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – The optimal duration of therapy has not been fully defined. For pollen SLIT, three years of consecutive therapy, but not shorter periods, confers at last two additional years of benefit. This is consistent with observations in other forms of allergen immunotherapy, which are usually administered for three to five years. For patients who are responding well to SLIT-tablet therapy and are willing to continue it, we advise three years of treatment. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Creticos PS, Balcer-Whaley SL, Moldt P, Pedersen O. Safety and efficacy of oral immunotherapy with a microencapsulated ragweed pollen extract (MRPE) in patients with ragweed-induced seasonal allergic rhinitis. Presented at the 27th Symposium of Collegium Internationale Allergologicum in Curacao, May 2008. (Abstract).</li><li><a class="nounderline abstract_t">Creticos PS, Balcer-Whaley SL, Moldt P, Pedersen O. Comparison of compositional differences and relative potency between different manufacturers of ragweed pollen extracts. J Allergy Clin Immunol 2007; 119:S57 (Abstract).</a></li><li><a class="nounderline abstract_t">Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558.</a></li><li><a class="nounderline abstract_t">Bousquet J. Sublingual immunotherapy: validated. Allergy 2006; 61(supplement 81):5.</a></li><li><a class="nounderline abstract_t">Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 Suppl 91:1.</a></li><li><a class="nounderline abstract_t">Goswami T, Jasti B, Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst 2008; 25:449.</a></li><li><a class="nounderline abstract_t">Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007; 28:35.</a></li><li><a class="nounderline abstract_t">Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740.</a></li><li><a class="nounderline abstract_t">Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167.</a></li><li><a class="nounderline abstract_t">Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013; 131:1342.</a></li><li><a class="nounderline abstract_t">Nolte H, Hébert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 2013; 110:450.</a></li><li><a class="nounderline abstract_t">Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127:974.</a></li><li><a class="nounderline abstract_t">Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2012; 130:886.</a></li><li><a class="nounderline abstract_t">Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162.</a></li><li><a class="nounderline abstract_t">Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599.</a></li><li><a class="nounderline abstract_t">Valovirta E, Jacobsen L, Ljørring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006; 61:1177.</a></li><li><a class="nounderline abstract_t">Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial. Curr Med Res Opin 2010; 26:2801.</a></li><li><a class="nounderline abstract_t">Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115:1184.</a></li><li><a class="nounderline abstract_t">Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007; 98:274.</a></li><li><a class="nounderline abstract_t">Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185.</a></li><li><a class="nounderline abstract_t">Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014; 134:568.</a></li><li><a class="nounderline abstract_t">Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014; 69:1181.</a></li><li><a class="nounderline abstract_t">Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA 2016; 315:1715.</a></li><li><a class="nounderline abstract_t">Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy 2016; 71:249.</a></li><li class="breakAll">Prescribing information for Oralair is available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM391580.pdf (Accessed on November 24, 2014).</li><li class="breakAll">Prescribing information for Grastek http://www.merck.com/product/usa/pi_circulars/g/grastek/grastek_pi.pdf (Accessed on April 15, 2014).</li><li class="breakAll">Prescribing information for Ragwitek is available at http://www.merck.com/product/usa/pi_circulars/r/ragwitek/ragwitek_pi.pdf (Accessed on April 24, 2014).</li><li><a class="nounderline abstract_t">Hansen TK, Poulsen LK, Stahl Skov P, et al. A randomized, double-blinded, placebo-controlled oral challenge study to evaluate the allergenicity of commercial, food-grade fish gelatin. Food Chem Toxicol 2004; 42:2037.</a></li><li><a class="nounderline abstract_t">Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2016; 138:1631.</a></li><li><a class="nounderline abstract_t">Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 2016; 137:444.</a></li><li><a class="nounderline abstract_t">Nelson H, Blaiss M, Nolte H, et al. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013; 68:252.</a></li><li><a class="nounderline abstract_t">Ellis AK, Tenn MW, Steacy LM, et al. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit. Ann Allergy Asthma Immunol 2018; 120:495.</a></li><li><a class="nounderline abstract_t">Couroux P, Ipsen H, Stage BS, et al. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. Allergy 2019; 74:361.</a></li><li><a class="nounderline abstract_t">Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124:150.</a></li><li><a class="nounderline abstract_t">Maloney J, Berman G, Gagnon R, et al. Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated. J Allergy Clin Immunol Pract 2016; 4:301.</a></li><li><a class="nounderline abstract_t">Röder E, Berger MY, Hop WC, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007; 119:892.</a></li><li><a class="nounderline abstract_t">de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012; 23:150.</a></li><li><a class="nounderline abstract_t">Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014; 133:751.</a></li><li><a class="nounderline abstract_t">Nolte H, Amar N, Bernstein DI, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol 2014; 113:93.</a></li><li><a class="nounderline abstract_t">Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012; 130:1327.</a></li><li><a class="nounderline abstract_t">Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol 2017; 139:1840.</a></li><li class="breakAll">www.fda.gov/vaccines-blood-biologics/allergenics/Oralair (Accessed on May 12, 2021).</li><li class="breakAll">www.fda.gov/vaccines-blood-biologics/allergenics/Grastek (Accessed on May 12, 2021).</li><li><a class="nounderline abstract_t">Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434.</a></li><li><a class="nounderline abstract_t">Bernstein DI, Kleine-Tebbe J, Nelson HS, et al. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. Ann Allergy Asthma Immunol 2018; 121:105.</a></li><li class="breakAll">www.fda.gov/vaccines-blood-biologics/allergenics/Odactra (Accessed on May 12, 2021).</li><li><a class="nounderline abstract_t">Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64.</a></li><li><a class="nounderline abstract_t">Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127:72.</a></li><li><a class="nounderline abstract_t">Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021.</a></li><li><a class="nounderline abstract_t">Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007; 2:117.</a></li><li><a class="nounderline abstract_t">Rodríguez-Pérez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008; 101:304.</a></li><li><a class="nounderline abstract_t">de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009; 64:963.</a></li><li><a class="nounderline abstract_t">Van Dyken AM, Smith PK, Fox TL. Clinical case of anaphylaxis with sublingual immunotherapy: house dust mite allergen. J Allergy Clin Immunol Pract 2014; 2:485.</a></li><li><a class="nounderline abstract_t">Epstein TG, Calabria C, Cox LS, Dreborg S. Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract 2017; 5:34.</a></li><li><a class="nounderline abstract_t">Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors. J Allergy Clin Immunol Pract 2019; 7:1996.</a></li><li><a class="nounderline abstract_t">Miehlke S, Alpan O, Schröder S, Straumann A. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol 2013; 7:363.</a></li><li><a class="nounderline abstract_t">Sampson HA. Peanut oral immunotherapy: is it ready for clinical practice? J Allergy Clin Immunol Pract 2013; 1:15.</a></li><li><a class="nounderline abstract_t">Hsieh FH. Oral food immunotherapy and iatrogenic eosinophilic esophagitis: an acceptable level of risk? Ann Allergy Asthma Immunol 2014; 113:581.</a></li><li><a class="nounderline abstract_t">Béné J, Ley D, Roboubi R, et al. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. Ann Allergy Asthma Immunol 2016; 116:583.</a></li><li><a class="nounderline abstract_t">Cafone J, Capucilli P, Hill DA, Spergel JM. Eosinophilic esophagitis during sublingual and oral allergen immunotherapy. Curr Opin Allergy Clin Immunol 2019; 19:350.</a></li><li><a class="nounderline abstract_t">Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802.</a></li><li><a class="nounderline abstract_t">Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181.</a></li><li><a class="nounderline abstract_t">Larsen TH, Poulsen LK, Melac M, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study. Allergy 2006; 61:1173.</a></li><li><a class="nounderline abstract_t">Nayak AS, Atiee GJ, Dige E, et al. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc 2012; 33:404.</a></li><li><a class="nounderline abstract_t">Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol 2014; 24:154.</a></li><li><a class="nounderline abstract_t">Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:45.</a></li><li><a class="nounderline abstract_t">Creticos PS, Bernstein DI, Casale TB, et al. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. J Allergy Clin Immunol Pract 2016; 4:1194.</a></li><li><a class="nounderline abstract_t">Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011; 22:803.</a></li><li><a class="nounderline abstract_t">Nakonechna A, Hills J, Moor J, et al. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy? Ann Allergy Asthma Immunol 2015; 114:73.</a></li><li><a class="nounderline abstract_t">Durham SR, GT-08 investigators. Sustained effects of grass pollen AIT. Allergy 2011; 66 Suppl 95:50.</a></li><li><a class="nounderline abstract_t">Nolte H, Bernstein DI, Kleine-Tebbe J, et al. Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round. J Allergy Clin Immunol Pract 2018; 6:1758.</a></li><li><a class="nounderline abstract_t">Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy 2014; 44:986.</a></li><li><a class="nounderline abstract_t">Yunginger JW, Gleich GJ. Measurement of ragweed antigen E by double antibody radioimmunoassay. J Allergy Clin Immunol 1972; 50:326.</a></li><li><a class="nounderline abstract_t">Leiferman KM, Gleich GJ, Jones RT. The cross-reactivity of IgE antibodies with pollen allergens. II. Analyses of various species of ragweed and other fall weed pollens. J Allergy Clin Immunol 1976; 58:140.</a></li><li><a class="nounderline abstract_t">Asero R, Weber B, Mistrello G, et al. Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: analysis of the allergenic differences between short and giant ragweed. J Allergy Clin Immunol 2005; 116:1036.</a></li><li><a class="nounderline abstract_t">Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25.</a></li><li class="breakAll">Prescribing information is available on the US FDA website. https://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM544382.pdf (Accessed on March 08, 2017).</li><li><a class="nounderline abstract_t">Casale TB, Canonica GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124:665.</a></li><li class="breakAll">Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. European Medicines Agency; London, 2009.</li><li><a class="nounderline abstract_t">Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317.</a></li><li><a class="nounderline abstract_t">Devillier P, Dreyfus JF, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014; 12:71.</a></li><li><a class="nounderline abstract_t">Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. J Allergy Clin Immunol 2016; 138:1081.</a></li><li><a class="nounderline abstract_t">Kim JY, Jang MJ, Kim DY, et al. Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison. J Allergy Clin Immunol Pract 2021; 9:4450.</a></li><li><a class="nounderline abstract_t">Quirino T, Iemoli E, Siciliani E, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996; 26:1253.</a></li><li><a class="nounderline abstract_t">Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288.</a></li><li><a class="nounderline abstract_t">Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82:485.</a></li><li><a class="nounderline abstract_t">Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011; 128:808.</a></li><li><a class="nounderline abstract_t">Mauro M, Russello M, Incorvaia C, et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007; 39:119.</a></li><li><a class="nounderline abstract_t">Tahamiler R, Saritzali G, Canakcioglu S, et al. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec 2008; 70:144.</a></li><li><a class="nounderline abstract_t">Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922.</a></li><li><a class="nounderline abstract_t">Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993; 71:461.</a></li><li><a class="nounderline abstract_t">Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017; 72:1597.</a></li><li><a class="nounderline abstract_t">Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis. JAMA Intern Med 2015; 175:1301.</a></li><li><a class="nounderline abstract_t">Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112:146.</a></li><li><a class="nounderline abstract_t">Murphy K, Gawchik S, Bernstein D, et al. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed 2013; 12:10.</a></li><li><a class="nounderline abstract_t">Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717.</a></li><li><a class="nounderline abstract_t">Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160.</a></li><li><a class="nounderline abstract_t">Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128:559.</a></li><li><a class="nounderline abstract_t">Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338.</a></li><li><a class="nounderline abstract_t">Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124:471.</a></li><li><a class="nounderline abstract_t">Zeldin RK, Rodriguez P, Abiteboul K, et al. Efficacy and saftey of 2-month pre-seasonal co-seasonal treatment with a 5-grass pollen allergen extrac sublingual tablet. Allergy Asthma Proc 2013; 34:298.</a></li><li><a class="nounderline abstract_t">Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014; 133:1608.</a></li><li><a class="nounderline abstract_t">Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 2015; 135:1494.</a></li><li><a class="nounderline abstract_t">Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol 2021; 147:1020.</a></li><li><a class="nounderline abstract_t">Nolte H, Waserman S, Ellis AK, et al. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season. J Allergy Clin Immunol Pract 2021; 9:1871.</a></li><li><a class="nounderline abstract_t">Gotoh M, Yonekura S, Imai T, et al. Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet. J Allergy Clin Immunol Pract 2019; 7:1287.</a></li><li><a class="nounderline abstract_t">Yonekura S, Gotoh M, Kaneko S, et al. Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: Evaluation of a phase II/III trial over three pollen dispersal seasons. Allergol Int 2019; 68:494.</a></li><li><a class="nounderline abstract_t">Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2020; 9:CD011293.</a></li><li><a class="nounderline abstract_t">Virchow JC, Backer V, Kuna P, et al. SQ HDM SLIT-tablet is effective in the treatment of allergic asthma; Results from a DBPC phase III trial (MITRA). Allergy 2014; 69:183.</a></li><li><a class="nounderline abstract_t">Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy 2019; 74:855.</a></li><li class="breakAll">Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: 2020 update. https://ginasthma.org/gina-reports/ (Accessed on September 23, 2020).</li><li><a class="nounderline abstract_t">Woehlk C, Ramu S, Sverrild A, et al. Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial. Am J Respir Crit Care Med 2023; 207:1161.</a></li><li><a class="nounderline abstract_t">Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018; 141:529.</a></li><li><a class="nounderline abstract_t">Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. Allergy 2019; 74:1317.</a></li><li><a class="nounderline abstract_t">Röder E, Berger MY, de Groot H, Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008; 38:1659.</a></li><li><a class="nounderline abstract_t">Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010; 126:668.</a></li><li><a class="nounderline abstract_t">Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012; 23:688.</a></li><li><a class="nounderline abstract_t">Kiel MA, Röder E, Gerth van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132:353.</a></li><li><a class="nounderline abstract_t">Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012; 2:280.</a></li><li><a class="nounderline abstract_t">Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010; 65:668.</a></li><li><a class="nounderline abstract_t">Kiotseridis H, Arvidsson P, Backer V, et al. Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax-a real life study. NPJ Prim Care Respir Med 2018; 28:4.</a></li><li><a class="nounderline abstract_t">Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014; 10:1309.</a></li><li><a class="nounderline abstract_t">Scadding GW, Calderon MA, Shamji MH, et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA 2017; 317:615.</a></li><li><a class="nounderline abstract_t">Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468.</a></li><li><a class="nounderline abstract_t">Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children--a 14-year study. Pediatrics 1968; 42:793.</a></li><li><a class="nounderline abstract_t">Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943.</a></li></ol></div><div id="topicVersionRevision">Topic 7538 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Creticos PS, Balcer-Whaley SL, Moldt P, Pedersen O. Safety and efficacy of oral immunotherapy with a microencapsulated ragweed pollen extract (MRPE) in patients with ragweed-induced seasonal allergic rhinitis. Presented at the 27th Symposium of Collegium Internationale Allergologicum in Curacao, May 2008. (Abstract).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of compositional differences and relative potency between different manufacturers of ragweed pollen extracts</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802362" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sublingual immunotherapy: validated</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20041860" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19062634" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sublingual drug delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17390755" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mucosal immunization application to allergic disease: sublingual immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21443635" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Systematic reviews of sublingual immunotherapy (SLIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19130937" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23622121" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23706715" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333346" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : House dust mite sublingual immunotherapy: results of a US trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22939758" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942563" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17951626" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942565" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050060" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940132" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378260" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409194" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797423" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25056584" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115376" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465232" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465232" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465232" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465232" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized, double-blinded, placebo-controlled oral challenge study to evaluate the allergenicity of commercial, food-grade fish gelatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521719" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26292778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205670" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29432967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30229939" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19523672" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26755098" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321581" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017365" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sublingual immunotherapy not effective in house dust mite-allergic children in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332263" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety and tolerability of a short ragweed sublingual immunotherapy tablet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122534" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864024" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864024" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864024" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890769" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29656145" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29656145" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21211642" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21211643" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675328" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sublingual immunotherapy: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18690957" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The safety of allergen specific sublingual immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814454" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222420" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017545" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical case of anaphylaxis with sublingual immunotherapy: house dust mite allergen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815065" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776526" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163646" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Induction of eosinophilic esophagitis by sublingual pollen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24229817" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Peanut oral immunotherapy: is it ready for clinical practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25304341" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Oral food immunotherapy and iatrogenic eosinophilic esophagitis: an acceptable level of risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067457" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058677" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Eosinophilic esophagitis during sublingual and oral allergen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630937" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409193" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942564" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026182" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25011352" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14674933" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349175" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21929600" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25457868" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668855" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sustained effects of grass pollen AIT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483037" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24708411" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4628905" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Measurement of ragweed antigen E by double antibody radioimmunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/956554" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The cross-reactivity of IgE antibodies with pollen allergens. II. Analyses of various species of ragweed and other fall weed pollens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275372" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: analysis of the allergenic differences between short and giant ragweed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765078" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Allergen immunotherapy: a practice parameter second update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765078" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Allergen immunotherapy: a practice parameter second update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766297" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recommendations for appropriate sublingual immunotherapy clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766297" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recommendations for appropriate sublingual immunotherapy clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298350" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24885894" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27527264" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34464748" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8955574" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041501" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353581" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641635" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17523385" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391573" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100188" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755664" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28493631" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26120825" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468255" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23725348" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285278" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19046761" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802126" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935764" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19647862" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Efficacy and saftey of 2-month pre-seasonal co-seasonal treatment with a 5-grass pollen allergen extrac sublingual tablet</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388010" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636947" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32890575" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33548518" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537561" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31257168" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: Evaluation of a phase II/III trial over three pollen dispersal seasons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926419" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Sublingual immunotherapy for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : SQ HDM SLIT-tablet is effective in the treatment of allergic asthma; Results from a DBPC phase III trial (MITRA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31095767" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31095767" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36701676" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28689794" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30589088" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18631346" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816199" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22985448" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Adherence to sublingual immunotherapy in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23651609" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22434716" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845569" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Sublingual immunotherapy: adherence based on timing and monitoring control visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29434271" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax-a real life study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25205329" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28196255" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441602" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Long-term clinical efficacy of grass-pollen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5685362" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The value of hyposensitization therapy for bronchial asthma in children--a 14-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620073" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
